Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  

12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
2015-005297-37: Bone Evaluation in women over 40 who Switch from Truvada/NNRTI to Triumeq

Ongoing
4
90
Europe
Tenofovir, Lamivudine, Efavirenz, Nevirapine, Etravirine, Rilpivirine, Film-coated tablet, Tablet, Triumeq, Truvada, Atripla, Eviplera
King's College Hospital NHS Foundation Trust, ViiV Healthcare Ltd
Human Immunodeficiency Virus, People infected with Human Immunodeficiency Virus (HIV), Diseases [C] - Immune System Diseases [C20]
 
 
2016-004646-29: DREAM study Estudio DREAM

Ongoing
4
64
Europe
Triumeq, Genvoya, Tablet, Triumeq, Genvoya
Fundación SEIMC-GESIDA, GILEAD Sciencies S.A.
HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02]
 
 
2017-000469-62: Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients. DGT-SOT Ensayo clínico piloto de un brazo para evaluar la eficacia, las interacciones farmacocinéticas y la seguridad del dolutegravir más 2 inhibidores nucleósidos de la Transcriptasa Inversa (NRTIs en su siglas en inglés) en pacientes trasplantados de órganos sólidos infectados por el VIH-1. DGT-SOT

Ongoing
4
20
Europe
Triumeq 50 mg/600 mg/300 mg comprimidos recubiertos con película dolutegravir/abacavir/lamivudina, Tivicay 50 mg, Truvada comprimidos recubiertos con película., Coated tablet, Tablet, Triumeq®, Dolutegravir 50 mg, 200 mg de emtricitabina y 245 mg de tenofovir disoproxil (equivalente a 300 mg de tenofovir disoproxil fumarato ó 136 mg de tenofovir).
Fundació Clínic per a la Recerca Biomèdica, ViiV Healthcare
HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., Diseases [C] - Virus Diseases [C02]
 
 
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos.

Ongoing
4
100
Europe
lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy
FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare
HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
2018-001158-82: DETOX Study Estudio DETOX

Ongoing
4
110
Europe
Symtuza, Tablet, Symtuza, Triumeq
Fundación SEIMC-GESIDA, JANSSEN CILAG S.A
HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02]
 
 
2019-004007-12: BIC CNS Study

Not yet recruiting
4
46
Europe
Biktarvy, Triumeq, Film-coated tablet, Biktarvy, Triumeq
University of Sussex, Gilead Sciences
HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02]
 
 
2016-000087-42: Triumeq As an Integrase Single Tablet Regimen in People with HIV who Inject Drugs

Not yet recruiting
4
50
Europe
Triumeq, Film-coated tablet, Triumeq
University College Dublin, ViiV Healthcare
Human Immunodeficiency Virus (HIV) infection, HIV infection, Diseases [C] - Immune System Diseases [C20]
 
 
NCT02131025: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Active, not recruiting
3
428
US, Canada
ABC/DTG/3TC FDC, Ongoing cART regimen
ViiV Healthcare, PPD, GlaxoSmithKline
Infection, Human Immunodeficiency Virus
04/15
10/15
FLAIR, NCT02938520 / 2016-001646-25: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Active, not recruiting
3
631
Europe, Canada, Japan, US, RoW
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline
HIV Infections
08/18
12/26
2018-004885-32: THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/LAMIVUDINE/ABACAVIR (D/L/A) TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) IN PATIENTS WITH SUPPRESSED VIRAL LOAD ON NEUROPSYCHIATRIC SIDE EFFECTS AND NEUROCOGNITIVE FUNCTION L’IMPATTO DEL PASSAGGIO DA DOLUTEGRAVIR/LAMIVUDINA/ABACAVIR (D/L/A) A BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE (B/F/TAF) NEI PAZIENTI IN TERAPIA ANTIRETROVIRALE CON HIVRNA SOPPRESSO SUGLI EVENTI AVVERSI NEUROPSICHIATRICI E SULLE FUNZIONI NEUROCOGNITIVE

Not yet recruiting
3
100
Europe
bictegravir/emtricitabina/tenofovir alafenamide, TRIUMEQ, [GS-9883-01], [dolutegravir/abacavir/lamivudina], Tablet, BIKTARVY, TRIUMEQ
AZIENDA OSPEDALIERA UNIVERSITARIA SENESE, Gilead Sciences
HIV-1 infection Infezione da HIV-1, Human immunodeficiency virus type 1 (HIV-1) infection Infezione da virus dell'immunodeficienza umana acquisita 1 (HIV-1), Diseases [C] - Virus Diseases [C02]
 
 
2020-001426-57: A study to compare whether giving two rather than three anti-HIV medicines daily to children and young people, aged between 2 and 15 years is assafe and effective in controlling their HIV infection Ensayo para comparar si la administración de dos en vez de tres fármacos anti-VIH diariamente en niños y pacientes jóvenes entre 2 y 15 años es tan segura y efectiva en el control de su infección por VIH.

Not yet recruiting
3
370
Europe
DTG/3TC DT, Dovato, Tivicay PD, Tivicay, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy, Dolutegravir, Dispersible tablet, Film-coated tablet, Capsule, hard, Dovato, TIVICAY PD, TIVICAY, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy
Fondazione Penta Onlus, ViiV Healthcare UK Limited
HIV Infection Infección por VIH, HIV Infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
NCT03016533: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Active, not recruiting
3
101
US, RoW
Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets, ABC/DTG/3TC film-coated dispersible tablets
ViiV Healthcare
HIV Infections
11/24
11/24

Download Options